Enliven Therapeutics, Inc. FCF to Net Income
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
| FCF to Net Income | 0.0% | 77.4% | 93.8% | 47.4% | 78.1% | 86.8% | 85.8% |
Enliven Therapeutics, Inc. (ELVN) FCF to Net Income comparison analysis
General
LTM FCF to Net Income
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
ELVN key stats
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.6 | 0.3 |
% margin | 0.0 0.0% | 0.0 0.0% | (0.0) 0.0% | (0.1) 0.0% | (0.1) 0.0% | (0.6) 0.0% | (0.3) 0.0% |
| Operating Expenses | 8.9 | 10.7 | 24.1 | 9.3 | 24.8 | 38.8 | 83.5 |
| Research & Development Expenses (R&D) | 7.9 | 8.2 | 19.0 | 8.2 | 20.5 | 31.0 | 64.6 |
| Selling, General & Administrative Expenses (SG&A) | 1.0 | 2.4 | 5.1 | 1.1 | 4.3 | 7.8 | 19.0 |
% margin | (8.9) 0.0% | (10.7) 0.0% | (24.1) 0.0% | (9.3) 0.0% | (24.8) 0.0% | (38.8) 0.0% | (83.5) 0.0% |
| Interest Income | 0.0 | 0.0 | 0.6 | 0.0 | 0.0 | 1.1 | 12.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax Income | 0.2 | (11.3) | (23.5) | (19.0) | (24.7) | (37.7) | (71.6) |
% effective tax rate | 0.2 100.0% | (0.8) 7.2% | 0.7 (2.8%) | (0.0) 0.2% | (0.0) 0.1% | 0.1 (0.2%) | 0.0 0.0% |
% margin | 0.0 0.0% | (11.3) 0.0% | (23.5) 0.0% | (18.9) 0.0% | (24.7) 0.0% | (37.8) 0.0% | (71.6) 0.0% |
| EPS | 0.00 | (2.62) | (5.43) | (14.14) | (3.17) | (6.03) | (2.01) |
| Diluted EPS | 0.00 | (2.62) | (5.43) | (14.14) | (3.17) | (6.03) | (2.01) |
% margin | 0.2 0.0% | (11.3) 0.0% | (23.4) 0.0% | (9.3) 0.0% | (24.6) 0.0% | (38.6) 0.0% | (81.9) 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Enliven Therapeutics, Inc.'s FCF to Net Income?
As of today, Microsoft Corp's last 12-month FCF to Net Income is 80.4%, based on the financial report for Sep 30, 2024 (Q3’2024). The average annual FCF to Net Income for Enliven Therapeutics, Inc. have been 189.1% over the past three years, and 171.2% over the past five years.
2) Is Enliven Therapeutics, Inc.'s FCF to Net Income Good?
As of today, Enliven Therapeutics, Inc.'s FCF to Net Income is 80.4%, which is lower than industry median of 84.8%. It indicates that Enliven Therapeutics, Inc.'s FCF to Net Income is Bad.